leukemia

[American Journal of Hematology] Investigators evaluated the most optimal donor for young acute leukemia patients with multiple donors available for allogeneic hematopoietic stem cell transplantation, including HLA-matched sibling donors, HLA-matched unrelated donors, haploidentical parental donors, and haploidentical sibling donors.

[Stem Cell Research & Therapy] The authors proposed a new hematopoietic stem and progenitor cell (HSPC) senescence model in vitro which they forecasted could be used to preliminary screen the drugs of the HSPC aging-related hemopathy and suggested cellular memory mechanism of HSPC aging.

[Trillium Therapeutics, Inc.] Trillium Therapeutics, Inc. announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.

[Journal of Controlled Release] Scientists highlight recent advance in targeted polymeric nanoformulations that are coated with varying ligands and loaded with different therapeutic agents for directing to distinct targets in hematological malignancies.

[Blood] To target CD70 on acute myeloid leukemia cells, researchers generated a panel of CD70-CAR T cells that contained a common single-chain variable fragment for antigen detection, but differed in size and flexibility of the extracellular spacer and in the transmembrane and the costimulatory domains.

[Nature Communications] Scientists developed and utilized a capture-based sequencing panel, which covered host hotspot genes and the full-length genome of human T-cell leukemia virus type-1, to investigate the clonal architecture of adult T-cell leukemia-lymphoma.